These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25003953)

  • 1. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors.
    Hubertus K; Mischnik M; Timmer J; Herterich S; Mark R; Moulard M; Walter U; Geiger J
    Eur J Pharmacol; 2014 Oct; 740():15-27. PubMed ID: 25003953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
    Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
    J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
    Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
    Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
    Glenn JR; White AE; Iyu D; Heptinstall S
    Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
    Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
    Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
    Kiriyama M; Ushikubi F; Kobayashi T; Hirata M; Sugimoto Y; Narumiya S
    Br J Pharmacol; 1997 Sep; 122(2):217-24. PubMed ID: 9313928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
    Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
    Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
    Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
    Srinivasan S; Mir F; Huang JS; Khasawneh FT; Lam SC; Le Breton GC
    J Biol Chem; 2009 Jun; 284(24):16108-16117. PubMed ID: 19346255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
    Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
    PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Prostanoids on Human Platelet Function: An Overview.
    Braune S; Küpper JH; Jung F
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cordycepin-enriched WIB801C from Cordyceps militaris inhibits ADP-induced [Ca(2+)] i mobilization and fibrinogen binding via phosphorylation of IP 3R and VASP.
    Lee DH; Kwon HW; Kim HH; Lim DH; Nam GS; Shin JH; Kim YY; Kim JL; Lee JJ; Kwon HK; Park HJ
    Arch Pharm Res; 2015 Jan; 38(1):81-97. PubMed ID: 25001901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved.
    Józefowski S; Bobek M; Marcinkiewicz J
    Int Immunopharmacol; 2003 Jun; 3(6):865-78. PubMed ID: 12781703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibitory effects of the NO donor MAHMA/NONOate on human platelets.
    Kobsar A; Simonis S; Klinker E; Koessler A; Kuhn S; Boeck M; Koessler J
    Eur J Pharmacol; 2014 Jul; 735():169-76. PubMed ID: 24780647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.